Advertisement
Screener

LEXICON PHARMACEUTICALS, INC. (LXRX) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

LEXICON PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities

LEXICON PHARMACEUTICALS, INC. (LXRX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-06

  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $4.90M, a 55.92% decline year-over-year.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$6.90M.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$5.65M, a 161.89% decline year-over-year.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$14.00M, a 257.86% decline year-over-year.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$30.22M, a 304.19% decline from fiscal 2024.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $14.80M, a 129.33% increase from fiscal 2023.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $6.45M, a 8392.11% increase from fiscal 2022.
  • LEXICON PHARMACEUTICALS, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $76.00K.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filedIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed
2026-06-30$4.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$2.00M
10-Q · filed 2026-08-06
-$7.64M
derived: sum of 3 quarters · filed 2026-08-06
-$21.65M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$6.90M
10-Q · filed 2026-05-07
-$12.55M
derived: sum of 2 quarters · filed 2026-05-07
-$26.55M
derived: sum of 3 quarters · filed 2026-05-07
-$15.43M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$5.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$19.65M
derived: sum of 2 quarters · filed 2026-03-05
-$8.53M
derived: sum of 3 quarters · filed 2026-08-06
-$30.22M
10-K · filed 2026-03-05
2025-09-30-$14.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$2.88M
derived: sum of 2 quarters · filed 2026-08-06
-$24.57M
10-Q · filed 2025-11-06
-$15.45M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$11.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$10.57M
10-Q · filed 2026-08-06
-$1.44M
derived: sum of 3 quarters · filed 2026-08-06
$7.43M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$21.69M
10-Q · filed 2026-05-07
-$12.56M
derived: sum of 2 quarters · filed 2026-05-07
-$3.69M
derived: sum of 3 quarters · filed 2026-05-07
$2.22M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$9.13M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$18.00M
derived: sum of 2 quarters · filed 2026-03-05
$23.91M
derived: sum of 3 quarters · filed 2026-03-05
$14.80M
10-K · filed 2026-03-05
2024-09-30$8.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$14.78M
derived: sum of 2 quarters · filed 2025-11-06
$5.67M
10-Q · filed 2025-11-06
$3.02M
derived: sum of 4 quarters · filed 2026-03-05
2024-06-30$5.91M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$3.20M
10-Q · filed 2025-08-06
-$5.85M
derived: sum of 3 quarters · filed 2026-03-05
$261.00K
derived: sum of 4 quarters · filed 2026-03-05
2024-03-31-$9.11M
10-Q · filed 2025-05-14
-$11.76M
derived: sum of 2 quarters · filed 2026-03-05
-$5.65M
derived: sum of 3 quarters · filed 2026-03-05
$116.00K
derived: sum of 4 quarters · filed 2026-03-05
2023-12-31-$2.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
$3.46M
derived: sum of 2 quarters · filed 2026-03-05
$9.22M
derived: sum of 3 quarters · filed 2026-03-05
$6.45M
10-K · filed 2026-03-05
2023-09-30$6.11M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$11.88M
derived: sum of 2 quarters · filed 2024-11-13
$9.11M
10-Q · filed 2024-11-13
$13.82M
derived: sum of 4 quarters · filed 2025-03-07
2023-06-30$5.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02
$3.00M
10-Q · filed 2024-08-02
$7.71M
derived: sum of 3 quarters · filed 2025-03-07
$8.52M
derived: sum of 4 quarters · filed 2025-03-07
2023-03-31-$2.77M
10-Q · filed 2024-05-02
$1.94M
derived: sum of 2 quarters · filed 2025-03-07
$2.75M
derived: sum of 3 quarters · filed 2025-03-07
$614.00K
derived: sum of 4 quarters · filed 2025-03-07
2022-12-31$4.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07
$5.52M
derived: sum of 2 quarters · filed 2025-03-07
$3.38M
derived: sum of 3 quarters · filed 2025-03-07
$76.00K
10-K · filed 2025-03-07
2022-09-30$810.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
-$1.33M
derived: sum of 2 quarters · filed 2023-11-08
-$4.64M
10-Q · filed 2023-11-08
-$5.36M
derived: sum of 4 quarters · filed 2024-03-25
2022-06-30-$2.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04
-$5.45M
10-Q · filed 2023-08-04
-$6.17M
derived: sum of 3 quarters · filed 2024-03-25
-$4.90M
derived: sum of 4 quarters · filed 2024-03-25
2022-03-31-$3.31M
10-Q · filed 2023-05-04
-$4.03M
derived: sum of 2 quarters · filed 2024-03-25
-$2.76M
derived: sum of 3 quarters · filed 2024-03-25
-$9.05M
derived: sum of 4 quarters · filed 2024-03-25
2021-12-31-$725.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25
$549.00K
derived: sum of 2 quarters · filed 2024-03-25
-$5.74M
derived: sum of 3 quarters · filed 2024-03-25
-$14.16M
10-K · filed 2024-03-25
2021-09-30$1.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$5.01M
derived: sum of 2 quarters · filed 2022-11-09
-$13.43M
10-Q · filed 2022-11-09
-$48.68M
derived: sum of 4 quarters · filed 2023-03-03
2021-06-30-$6.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
-$14.71M
10-Q · filed 2022-08-03
-$49.96M
derived: sum of 3 quarters · filed 2023-03-03
-$68.21M
derived: sum of 4 quarters · filed 2023-03-03
2021-03-31-$8.42M
10-Q · filed 2022-05-05
-$43.67M
derived: sum of 2 quarters · filed 2023-03-03
-$61.92M
derived: sum of 3 quarters · filed 2023-03-03
-$44.52M
derived: sum of 4 quarters · filed 2023-03-03
2020-12-31-$35.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
-$53.50M
derived: sum of 2 quarters · filed 2023-03-03
-$36.11M
derived: sum of 3 quarters · filed 2023-03-03
-$20.97M
10-K · filed 2023-03-03
2020-09-30-$18.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
-$856.00K
derived: sum of 2 quarters · filed 2021-11-09
$14.28M
10-Q · filed 2021-11-09
$35.02M
derived: sum of 4 quarters · filed 2022-03-10
2020-06-30$17.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06
$32.53M
10-Q · filed 2021-08-06
$53.27M
derived: sum of 3 quarters · filed 2022-03-10
$66.47M
derived: sum of 4 quarters · filed 2022-03-10
2020-03-31$15.14M
10-Q · filed 2021-05-06
$35.88M
derived: sum of 2 quarters · filed 2022-03-10
$49.08M
derived: sum of 3 quarters · filed 2022-03-10
$43.41M
derived: sum of 4 quarters · filed 2022-03-10
2019-12-31$20.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
$33.94M
derived: sum of 2 quarters · filed 2022-03-10
$28.27M
derived: sum of 3 quarters · filed 2022-03-10
$20.10M
10-K · filed 2022-03-10
2019-09-30$13.20M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30
$7.53M
derived: sum of 2 quarters · filed 2020-10-30
-$645.00K
10-Q · filed 2020-10-30
-$15.65M
derived: sum of 4 quarters · filed 2021-03-12
2019-06-30-$5.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29
-$13.84M
10-Q · filed 2020-07-29
-$28.85M
derived: sum of 3 quarters · filed 2021-03-12
-$26.91M
derived: sum of 4 quarters · filed 2021-03-12
2019-03-31-$8.17M
10-Q · filed 2020-04-27
-$23.18M
derived: sum of 2 quarters · filed 2021-03-12
-$21.24M
derived: sum of 3 quarters · filed 2021-03-12
-$37.47M
derived: sum of 4 quarters · filed 2021-03-12
2018-12-31-$15.01M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$13.07M
derived: sum of 2 quarters · filed 2021-03-12
-$29.30M
derived: sum of 3 quarters · filed 2021-03-12
-$19.91M
10-K · filed 2021-03-12
-$18.86M
10-K · filed 2019-03-15
2018-09-30$1.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$14.29M
derived: sum of 2 quarters · filed 2019-11-07
-$4.91M
10-Q · filed 2019-11-07
-$4.70M
10-Q · filed 2018-11-01
-$5.04M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30-$16.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
-$6.84M
10-Q · filed 2019-08-01
-$6.64M
10-Q · filed 2018-07-30
-$6.98M
derived: sum of 3 quarters · filed 2020-03-12
$3.55M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$9.38M
10-Q · filed 2019-05-01
$9.47M
10-Q · filed 2018-05-03
$9.24M
derived: sum of 2 quarters · filed 2020-03-12
$19.78M
derived: sum of 3 quarters · filed 2020-03-12
$22.21M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31-$137.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$10.39M
derived: sum of 2 quarters · filed 2020-03-12
$12.83M
derived: sum of 3 quarters · filed 2020-03-12
-$11.88M
10-K · filed 2020-03-12
$7.17M
10-K · filed 2018-03-01
2017-09-30$10.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$12.96M
derived: sum of 2 quarters · filed 2018-11-01
-$11.74M
10-Q · filed 2018-11-01
-$16.86M
derived: sum of 4 quarters · filed 2019-03-15
2017-06-30$2.43M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30
-$22.27M
10-Q · filed 2018-07-30
$22.27M
10-Q · filed 2017-08-01
-$27.39M
derived: sum of 3 quarters · filed 2019-03-15
-$2.87M
derived: sum of 4 quarters · filed 2019-03-15
2017-03-31-$24.70M
10-Q · filed 2018-05-03
$24.70M
10-Q · filed 2017-05-04
-$29.82M
derived: sum of 2 quarters · filed 2019-03-15
-$5.30M
derived: sum of 3 quarters · filed 2019-03-15
-$7.28M
derived: sum of 4 quarters · filed 2019-03-15
2016-12-31-$5.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
$19.40M
derived: sum of 2 quarters · filed 2019-03-15
$17.42M
derived: sum of 3 quarters · filed 2019-03-15
$13.58M
10-K · filed 2019-03-15
-$27.65M
10-K · filed 2017-03-06
2016-09-30$24.52M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$22.54M
derived: sum of 2 quarters · filed 2017-11-08
$18.70M
10-Q · filed 2017-11-08
-$18.70M
10-Q · filed 2016-11-07
$15.43M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30-$1.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-01
-$5.82M
10-Q · filed 2017-08-01
-$9.10M
derived: sum of 3 quarters · filed 2018-03-01
-$15.35M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31-$3.84M
10-Q · filed 2017-05-04
-$7.12M
derived: sum of 2 quarters · filed 2018-03-01
-$13.37M
derived: sum of 3 quarters · filed 2018-03-01
-$11.34M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31-$3.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
-$9.53M
derived: sum of 2 quarters · filed 2018-03-01
-$7.50M
derived: sum of 3 quarters · filed 2018-03-01
-$6.20M
10-K · filed 2018-03-01
2015-09-30-$6.25M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$4.23M
derived: sum of 2 quarters · filed 2016-11-07
-$2.92M
10-Q · filed 2016-11-07
$2.40M
derived: sum of 4 quarters · filed 2017-03-06
2015-06-30$2.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04
$3.33M
10-Q · filed 2016-08-04
$8.65M
derived: sum of 3 quarters · filed 2017-03-06
$4.75M
derived: sum of 4 quarters · filed 2017-03-06
2015-03-31$1.30M
10-Q · filed 2016-05-05
$6.62M
derived: sum of 2 quarters · filed 2017-03-06
$2.73M
derived: sum of 3 quarters · filed 2017-03-06
-$1.84M
derived: sum of 4 quarters · filed 2017-03-06
2014-12-31$5.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06
$1.43M
derived: sum of 2 quarters · filed 2017-03-06
-$3.14M
derived: sum of 3 quarters · filed 2017-03-06
-$1.27M
10-K · filed 2017-03-06
2014-09-30-$3.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
-$8.46M
derived: sum of 2 quarters · filed 2015-11-09
-$6.59M
10-Q · filed 2015-11-09
-$3.02M
derived: sum of 4 quarters · filed 2016-03-11
2014-06-30-$4.57M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
-$2.69M
10-Q · filed 2015-08-07
$873.00K
derived: sum of 3 quarters · filed 2016-03-11
-$3.56M
derived: sum of 4 quarters · filed 2016-03-11
2014-03-31$1.88M
10-Q · filed 2015-05-05
$5.44M
derived: sum of 2 quarters · filed 2016-03-11
$1.01M
derived: sum of 3 quarters · filed 2016-03-11
-$2.15M
derived: sum of 4 quarters · filed 2016-03-11
2013-12-31$3.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11
-$868.00K
derived: sum of 2 quarters · filed 2016-03-11
-$4.02M
derived: sum of 3 quarters · filed 2016-03-11
-$3.12M
10-K · filed 2016-03-11
2013-09-30-$4.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
-$7.59M
derived: sum of 2 quarters · filed 2014-11-06
-$6.68M
10-Q · filed 2014-11-06
-$7.58M
derived: sum of 4 quarters · filed 2015-03-12
2013-06-30-$3.16M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
-$2.25M
10-Q · filed 2014-08-07
-$3.14M
derived: sum of 3 quarters · filed 2015-03-12
-$1.57M
derived: sum of 4 quarters · filed 2015-03-12
2013-03-31$905.00K
10-Q · filed 2014-05-08
$13.00K
derived: sum of 2 quarters · filed 2015-03-12
$1.58M
derived: sum of 3 quarters · filed 2015-03-12
$1.05M
derived: sum of 4 quarters · filed 2015-03-12
2012-12-31-$892.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$678.00K
derived: sum of 2 quarters · filed 2015-03-12
$144.00K
derived: sum of 3 quarters · filed 2015-03-12
$995.00K
10-K · filed 2015-03-12
2012-09-30$1.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12
$1.04M
derived: sum of 2 quarters · filed 2013-11-12
$1.89M
10-Q · filed 2013-11-12
-$4.65M
derived: sum of 4 quarters · filed 2014-03-07
2012-06-30-$534.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01
$317.00K
10-Q · filed 2013-08-01
-$6.22M
derived: sum of 3 quarters · filed 2014-03-07
-$7.69M
derived: sum of 4 quarters · filed 2014-03-07
2012-03-31$851.00K
10-Q · filed 2013-05-10
-$5.69M
derived: sum of 2 quarters · filed 2014-03-07
-$7.15M
derived: sum of 3 quarters · filed 2014-03-07
-$5.67M
derived: sum of 4 quarters · filed 2014-03-07
2011-12-31-$6.54M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
-$8.01M
derived: sum of 2 quarters · filed 2014-03-07
-$6.52M
derived: sum of 3 quarters · filed 2014-03-07
-$10.37M
10-K · filed 2014-03-07
2011-09-30-$1.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
$25.00K
derived: sum of 2 quarters · filed 2012-11-07
-$3.82M
10-Q · filed 2012-11-07
-$1.90M
derived: sum of 4 quarters · filed 2013-03-11
2011-06-30$1.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02
-$2.36M
10-Q · filed 2012-08-02
-$433.00K
derived: sum of 3 quarters · filed 2013-03-11
$1.42M
derived: sum of 4 quarters · filed 2013-03-11
2011-03-31-$3.85M
10-Q · filed 2012-05-03
-$1.92M
derived: sum of 2 quarters · filed 2013-03-11
-$70.00K
derived: sum of 3 quarters · filed 2013-03-11
2010-12-31$1.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11
$3.78M
derived: sum of 2 quarters · filed 2013-03-11
$5.24M
10-K · filed 2013-03-11
2010-09-30$1.85M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01
$3.31M
10-Q · filed 2011-11-01
2010-06-30$1.46M
10-Q · filed 2011-08-09
2009-12-31$2.79M
10-K · filed 2012-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
GERON CORP (GERN)United States$0.803B-12.14
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78